Quick Answer
COSCIENS Biopharma Inc. reported R&D Expense of $2.95 million for fiscal year 2025.
COSCIENS Biopharma Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $2.95M | -64.5% |
| 2024 | $8.30M | +307.1% |
| 2023 | $2.04M | +48.8% |
| 2022 | $1.37M | -79.1% |
| 2021 | $6.57M | +336.5% |
| 2020 | $1.51M | -18.0% |
| 2019 | $1.84M | -37.3% |
| 2018 | $2.93M | -72.6% |
| 2017 | $10.70M | -35.1% |
| 2016 | $16.50M | -4.3% |
| 2015 | $17.23M | — |
- COSCIENS Biopharma Inc. showed a decrease of -64.5% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, COSCIENS Biopharma Inc.’s r&d expense has declined by 82.9% (from $17.23 million to $2.95 million).
- The most recent figure is from COSCIENS Biopharma Inc.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: